Log in

NASDAQ:AUXL - Auxilium Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.32 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men's healthcare. The company's products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:AUXL
CUSIP05334D10
Phone+1-484-3215900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive AUXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUXL and its competitors with MarketBeat's FREE daily newsletter.


Auxilium Pharmaceuticals (NASDAQ:AUXL) Frequently Asked Questions

What is Auxilium Pharmaceuticals' stock symbol?

Auxilium Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUXL."

How were Auxilium Pharmaceuticals' earnings last quarter?

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) released its earnings results on Thursday, October, 30th. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.30. The biopharmaceutical company earned $109.60 million during the quarter, compared to the consensus estimate of $101.02 million. Auxilium Pharmaceuticals's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.17 earnings per share. View Auxilium Pharmaceuticals' Earnings History.

Has Auxilium Pharmaceuticals been receiving favorable news coverage?

Press coverage about AUXL stock has been trending extremely negative recently, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Auxilium Pharmaceuticals earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Auxilium Pharmaceuticals.

Who are some of Auxilium Pharmaceuticals' key competitors?

What other stocks do shareholders of Auxilium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Auxilium Pharmaceuticals investors own include Repros Therapeutics (RPRX), Yelp (YELP), Aegerion Pharmaceuticals (AEGR), Anacor Pharmaceuticals (ANAC), MannKind (MNKD), Netflix (NFLX), Altaba (AABA), Acorda Therapeutics (ACOR), Agios Pharmaceuticals (AGIO) and Akamai Technologies (AKAM).

What is Auxilium Pharmaceuticals' official website?

The official website for Auxilium Pharmaceuticals is http://www.auxilium.com/.

How can I contact Auxilium Pharmaceuticals?

Auxilium Pharmaceuticals' mailing address is 640 Lee Rd, CHESTERBROOK, PA 19087-5636, United States. The biopharmaceutical company can be reached via phone at +1-484-3215900.


MarketBeat Community Rating for Auxilium Pharmaceuticals (NASDAQ AUXL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  462
MarketBeat's community ratings are surveys of what our community members think about Auxilium Pharmaceuticals and other stocks. Vote "Outperform" if you believe AUXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUXL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel